🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Melbourne
Clinical trial register · Australia

Clinical Trials in Melbourne, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Australia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3335 matching records held by the registry are in this view. Synced 30 Sep 2026, 03:17 UTC
3335
Studies in scope
all four open statuses
1809
Recruiting now
open to new participants
761
Lead sponsors
across recruiting studies
Top sites
Melbourne 31 Sydney 6 Brisbane 3 Adelaide 3 Camperdown 2
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca54 Janssen Research & Development, LLC37 Merck Sharp & Dohme LLC32 Peter MacCallum Cancer Centre, Australia31 Novartis Pharmaceuticals28 Clear sponsor filter
Site location
Melbourne31 Sydney6 Brisbane3 Adelaide3 Camperdown2
All 21 locations
Target enrolment
to

Trials with a site in Melbourne

31 of 3335 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Australia
Start
Not yet open
Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma
NCT07840001Locally Advanced Clear Cell Renal Cell Carcinoma
DrugsBelzutifan·Pembrolizumab
Peter MacCallum Cancer Centre, Australia
Phase 2
30
Melbourne
2026-12
Not yet open
Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary
NCT07434180Cancer of Unknown Primary
Drug177Lu-FAP-2286
Peter MacCallum Cancer Centre, Australia
Phase 2
20
Melbourne
2026-06
Recruiting
Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease
NCT07541391Relapsed/Refractory Multiple Myeloma
Peter MacCallum Cancer Centre, Australia
Phase 1
12
Melbourne
2026-05
Not yet open
Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)
NCT07527819Triple Negative Breast Cancer (TNBC)
Peter MacCallum Cancer Centre, Australia
Observational
75
Camperdown, Sydney, Adelaide, Hobart, Box Hill, Clayton, Melbourne, Nedlands
2026-04-08
Recruiting
Novel Treatment of Radiation Associated Dysphagia With Statins
NCT07217938Radiation-associated Dysphagia, Head &Amp; Neck Cancer
DrugPravastatin
Peter MacCallum Cancer Centre, Australia
Phase 2
48
Melbourne
2025-12-05
Recruiting
Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and Fever
NCT07051525Leukemia, CART Therapy, Transplantation, Stem Cell, Infections, Bacterial
Peter MacCallum Cancer Centre, Australia
Not applicable
214
Melbourne
2025-12-03
Recruiting
A Study to Describe the Effect of Photobiomodulation (Low Level Laser Therapy) in Reducing the Severity and Incidence of Oral Mucositis (Oral Ulceration) in Oral Cancer Patients Undergoing Radiation Treatment
NCT07387978Oral Mucositis
Peter MacCallum Cancer Centre, Australia
Not applicable
30
Melbourne
2025-11-26
Active, closed
EQUIP - Evaluation of Quality of Imaging on a Next-generation Total Body Pet Scan in Comparison to Conventional PET
NCT07263815Cancer
Peter MacCallum Cancer Centre, Australia
Not applicable
25
Melbourne
2025-11-24
Not yet open
Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer
NCT07090369Metastatic Castrate Resistant Prostate Cancer (mCRPC)
DrugsOlaparib·Pembrolizumab
Peter MacCallum Cancer Centre, Australia
Phase 1
20
Melbourne
2025-11-01
Recruiting
IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma
NCT07138222Melanoma (Skin Cancer)
Peter MacCallum Cancer Centre, Australia
Observational
80
Sydney, Brisbane, Cairns, Melbourne
2025-09-11
Not yet open
Home-Based Photo-Biomodulation for Management of Lymphoedema and Radiation Fibrosis in Patients After Head and Neck Cancer: A Single-Arm Feasibility Trial
NCT07139782Head and Neck Cancer
Peter MacCallum Cancer Centre, Australia
Not applicable
30
Melbourne
2025-09-04
Recruiting
Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
NCT06812715Chronic Lymphocytic Leukemia
DrugPirtobrutinib
Peter MacCallum Cancer Centre, Australia
Phase 2
40
Melbourne
2025-05-05
Recruiting
MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
NCT06414148Relapsed/Refractory Large B-cell Lymphoma
DrugEpcoritamab
Peter MacCallum Cancer Centre, Australia
Phase 2
40
Camperdown, Westmead, Herston, Melbourne, Murdoch
2024-05-14
Recruiting
Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy
NCT05560659Oligometastatic Prostate Cancer
DrugLu-PSMA
Peter MacCallum Cancer Centre, Australia
Phase 2
92
St Leonards, Melbourne
2023-12-14
Active, closed
CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study
NCT05666700Extramedullary Myeloma
Peter MacCallum Cancer Centre, Australia
Phase 1
10
Melbourne
2023-12-08
Recruiting
Siderophore-labelled Positron Emission Tomography for Correlating Invasive Fungal InfeCtions
NCT06105411Invasive Fungal Infections
Peter MacCallum Cancer Centre, Australia
Observational
10
Melbourne
2023-12-01
Recruiting
Metabolic Phenotypes in Melanoma
NCT05570227Melanoma
Peter MacCallum Cancer Centre, Australia
Not applicable
240
Melbourne
2023-06-27
Active, closed
Deep sequencIng in Cutaneous Squamous CEll caRciNomas
NCT05878288Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Neoplasms, Non-melanoma Skin Cancer
DrugCemiplimab
Peter MacCallum Cancer Centre, Australia
Phase 2
11
Melbourne
2023-05-26
Recruiting
EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T
NCT05521412Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Peter MacCallum Cancer Centre, Australia
Phase 1/2
66
Melbourne
2022-09-29
Active, closed
Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer
NCT05383079Metastatic Castration-resistant Prostate Cancer, MCRPC, Prostate Cancer
DrugXofigo
Peter MacCallum Cancer Centre, Australia
Phase 1/2
36
Melbourne
2022-09-13
Active, closed
Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer
NCT05340374Metastatic Castration-resistant Prostate Cancer, mCRPC
DrugsCabazitaxel·Lu-PSMA
Peter MacCallum Cancer Centre, Australia
Phase 1/2
35
Sydney, Melbourne
2022-07-14
Recruiting
Diagnosis and Phenotype Characterisation Using Genomics in Patients With Inherited Bone Marrow Failure (IBMDx Study)
NCT05196789Inherited BMF Syndrome, Inherited Platelet Disorder, Hematologic Diseases
Peter MacCallum Cancer Centre, Australia
Observational
350
Melbourne
2022-03-18
Active, closed
PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI
NCT05154162Prostate Cancer
Peter MacCallum Cancer Centre, Australia
Phase 3
660
Sydney, Brisbane, Adelaide, Melbourne
2022-03-02
Recruiting
PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours
NCT05053854Neuroendocrine Tumors
DrugTalazoparib
Peter MacCallum Cancer Centre, Australia
Phase 1
24
Melbourne
2021-12-08
Active, closed
ProsTIC Registry of Men Treated With PSMA Theranostics
NCT04769817Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Peter MacCallum Cancer Centre, Australia
Observational
500
Melbourne
2021-05-19
Active, closed
Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
NCT04430192Prostatic Neoplasms
DrugLu-PSMA
Peter MacCallum Cancer Centre, Australia
Phase 1/2
20
Melbourne
2020-08-06
Active, closed
In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
NCT04343885Metastatic Hormone Naive Prostate Cancer
DrugsLu-PSMA·Docetaxel
Peter MacCallum Cancer Centre, Australia
Phase 2
130
Liverpool, St Leonards, Sydney, Brisbane, Adelaide, Malvern, Melbourne, Prahran
2020-04-21
Active, closed
Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma
NCT04234061Mantle Cell Lymphoma Recurrent
Peter MacCallum Cancer Centre, Australia
Phase 2
20
Melbourne
2020-04-07
Active, closed
Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer
NCT03900884Breast Neoplasm Female
DrugsPalbociclib·Letrozole·Venetoclax
Peter MacCallum Cancer Centre, Australia
Phase 1
17
Melbourne
2019-09-25
Active, closed
Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma
NCT03980171Follicular Lymphoma
DrugsVenclyxto·Venclexta·Obinutuzumab·Lenalidomide
Peter MacCallum Cancer Centre, Australia
Phase 1/2
50
Townsville, Melbourne, Nedlands
2019-08-19
Active, closed
177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
NCT03874884Metastatic Castration Resistant Prostate Cancer (mCRPC)
DrugOlaparib
Peter MacCallum Cancer Centre, Australia
Phase 1
70
Sydney, Melbourne
2019-07-09
Rows per page Showing 1–31 of 31
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Australian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-australia/city/melbourne

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Australia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,335 studies in total at the last sync on 30 Sep 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 31 of those studies with a site in Melbourne that also match the filters currently applied.

How many clinical trials are recruiting in Melbourne?

13 of the 31 studies on this page are recruiting new participants as of the 30 Sep 2026, 03:17 UTC sync. A further 5 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Melbourne), 31 studies
PhaseStudiesRecruitingShare
Phase 29429%
Phase 16219.4%
Not applicable5316.1%
Observational5316.1%
Phase 1/25116.1%
Phase 3103.2%

Most active sponsors

Lead sponsors with the most studies (Melbourne)
Lead sponsorStudiesRecruiting
Peter MacCallum Cancer Centre, Australia3113
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.